Effect of nalbuphine on median effective dose of sufentanil in postoperative analgesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014603

Enrollment

Unknown

Registered

2018-01-23

Start date

2018-02-01

Completion date

Unknown

Last updated

2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

N3:nalbuphine+sufentanil

S:sufentanil

N1:nalbuphine+sufentanil

N2:nalbuphine+sufentanil

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. patients aged 18-70 years old, udergoing laparoscopic hysterctomy surgery; 2. patients with ASA ranging from grade I to grade II; 3. BMI 18-25kg/m2.

Exclusion criteria

Exclusion criteria: 1. patient with opioids allergy or using opioids recently; 2. patient with history of respiratory system disease,circulation system disease and digestion system disease; 3. patient with mental disease; 4. patient who can not understand the visual analogue score (VAS); 5. patient who can not understand how to use intravenous controlled analgesia (PCA)

Design outcomes

Primary

Measure	Time frame
VAS;OAA/S;respiratory deprssion;nausea and vomiting;	—

Secondary

Measure	Time frame
First exhaust and defecation time;First time to eat;	—

Countries

China

Contacts

Public ContactZhentao Sun

The First Affiliated Hospital of Zhengzhou University

gentlesun@126.com+86 13603455483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026